Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan;21(1):1-2.
doi: 10.3988/jcn.2024.0527.

Monoclonal Antibodies-A New Horizon in Alzheimer's Treatment

Hyuk Sung Kwon  1 , Seong-Ho Koh  1   2
Affiliations
Editorial

Monoclonal Antibodies-A New Horizon in Alzheimer's Treatment

Hyuk Sung Kwon et al. J Clin Neurol. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Main targets of the anti-amyloid monoclonal antibodies and transformation of Aβ monomers into oligomers, protofibrils, fibrils, and plaques. Aβ, amyloid-beta.
See this image and copyright information in PMC

References

    1. Bailey M, Ilchovska ZG, Hosseini AA, Jung J. Impact of apolipoprotein E ε4 in Alzheimer’s disease: a meta-analysis of voxel-based morphometry studies. J Clin Neurol. 2024;20:469–477. - PMC - PubMed
    1. Park C, Joo G, Roh M, Shin S, Yum S, Yeo NY, et al. Predicting the progression of mild cognitive impairment to Alzheimer’s dementia using recurrent neural networks with a series of neuropsychological tests. J Clin Neurol. 2024;20:478–486. - PMC - PubMed
    1. Heo S, Yoon CW, Kim SY, Kim WR, Na DL, Noh Y. Alterations of structural network efficiency in early-onset and late-onset Alzheimer’s disease. J Clin Neurol. 2024;20:265–275. - PMC - PubMed
    1. Abbott A. Could drugs prevent Alzheimer’s? These trials aim to find out. Nature. 2022;603:216–219. - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. - PubMed

Publication types

LinkOut - more resources